Lubos D.
- Country
- Slovakia
- Department
- NA
Research Overview
- Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab, Rituximab, and Lenalidomide Versus Chemoimmunotherapy in Untreated Follicular Lymphoma
- Phase 3 Open-Label Evaluation of Epcoritamab with Rituximab and Lenalidomide in Relapsed/Refractory Follicular Lymphoma
- Phase 3 Randomized Double-Blind Study of Ibuzatrelvir and Remdesivir in Severely Immunocompromised Adults with Symptomatic COVID-19
Data & Insights
Has run more than one trial at 49 of 196 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator concentrates on hormone receptor‑positive and HER2‑negative disease entities across the disease continuum.
- Advanced breast cancer
- HR‑positive/HER2‑negative metastatic breast cancer
- Triple‑negative breast cancer
Efforts include evaluating novel oral agents, endocrine combinations, and targeted therapies.
Prostate Cancer Innovations
Research activity emphasizes both castration‑sensitive and castration‑resistant disease phenotypes.
- Metastatic castration‑sensitive prostate cancer
- Metastatic castration‑resistant prostate cancer
- Oligometastatic prostate cancer
Key interests involve androgen‑axis targeting agents and radioligand strategies.
Lung Cancer and Thoracic Oncology
The focus extends to non‑small cell lung cancer subgroups defined by molecular and immunologic markers.
- Non‑small cell lung cancer
- PD‑L1‑positive advanced lung cancer
- KRAS‑mutated metastatic colorectal cancer with lung involvement
Investigations include targeted inhibitors, immunotherapy combinations, and biomarker‑driven approaches.
Hematologic Malignancies
Clinical work targets both lymphoma and leukemia subsets with distinct genetic backgrounds.
- Diffuse large B‑cell lymphoma
- Follicular lymphoma
- Chronic lymphocytic leukemia
- Acute lymphoblastic leukemia
Therapeutic strategies explore antibody‑drug conjugates, bispecific antibodies, and novel kinase inhibitors.
Gastrointestinal and Melanoma Oncology
Activities span colorectal, biliary, pancreatic, and melanoma indications, often with actionable mutations.
- Colorectal cancer with BRAF V600E mutation
- Advanced HER2‑expressing biliary tract cancer
- Metastatic melanoma with BRAF V600E/K mutation
- Unresectable pancreatic ductal adenocarcinoma
Research investigates combination regimens that integrate targeted agents, immunotherapies, and chemotherapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.